Predictors for Successful Weight Reduction During Treatment with Dapagliflozin Among Patients with Type 2 Diabetes Mellitus in Primary Care

Overview

Journal BMC Prim Care

Specialties Health Services
Public Health

Date 2022 May 27

PMID 35624416

Authors

Youn Huh

Young Sik Kim

Affiliations

Soon will be listed here.

Abstract

Aims: Studies on factors affecting weight loss effect after start of dapagliflozin in type 2 diabetes mellitus (T2DM) patients are few. The aim of this study was to identify if there were any patient characteristics that could predict weight loss after starting treatment with dapagliflozin.

Methods: The study included 200 Korean patients with T2DM who were prescribed dapagliflozin in a family medicine clinic during 2014-2019. We studied patients for 1 year after starting dapagliflozin treatment. Data were collected from medical records. Clinically meaningful weight reduction was defined as ≥3% decrease in body weight and odds ratios (ORs) and 95% confidence intervals (CIs) for succeeding this weight reduction was calculated for different baseline characteristics.

Results: In total, 113 (56.5%) patients were male. Weight loss of ≥3% in 1 year treatment with dapagliflozin was achieved in 122 (61%) patients. The likelihood of this level of weight loss was significantly increased with regular exercise (OR 2.13, 95% CI 1.07-4.25), with concomitant metformin treatment (OR 2.90, 95% CI 1.23-6.80), and in patients with normal renal function (OR 13.84, 95% CI 1.33-144.26). Patients receiving sulfonylurea treatment were less likely to achieve ≥3% weight reduction (OR 0.39, 95 CI 0.19-0.79).

Conclusions: T2DM patients that performed regular exercise, had normal renal function and were receiving metformin were more likely to have clinically meaningful body weight reduction after one year treatment with dapagliflozin.

Citing Articles

Impact of baseline dietary quality on the efficacy of a dietitian-guided weight reduction program.

Lin Y, Chen Y, Chen Y, Hsieh H, Chen Y, Wang W BMC Nutr. 2024; 10(1):149.

PMID: 39533446 PMC: 11555817. DOI: 10.1186/s40795-024-00956-5.

Safety and Efficacy of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: Multicentre Retrospective Study on Echocardiographic Parameters and Biomarkers of Heart Congestion.

Battistoni I, Pongetti G, Falchetti E, Giannini I, Olivieri R, Gioacchini F J Clin Med. 2024; 13(12).

PMID: 38930049 PMC: 11204467. DOI: 10.3390/jcm13123522.

Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients.

Danpanichkul P, Manosroi W, Nilsirisuk T, Tosukhowong T Front Endocrinol (Lausanne). 2024; 14:1251798.

PMID: 38327904 PMC: 10849059. DOI: 10.3389/fendo.2023.1251798.

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives.

Barreto J, Campos-Staffico A, Nadruz W, Quinaglia T, Sposito A Front Clin Diabetes Healthc. 2023; 4:1243530.

PMID: 37822556 PMC: 10562622. DOI: 10.3389/fcdhc.2023.1243530.

References

Wilding J, Bailey C, Rigney U, Blak B, Beekman W, Emmas C . Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. Diabetes Ther. 2016; 7(4):695-711. PMC: 5118232. DOI: 10.1007/s13300-016-0193-8. View

. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K . Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter,.... Expert Opin Pharmacother. 2014; 15(6):749-66. DOI: 10.1517/14656566.2014.887680. View

Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde A . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3):1020-31. DOI: 10.1210/jc.2011-2260. View

Masuo K, Mikami H, Ogihara T, Tuck M . Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001; 14(6 Pt 1):530-8. DOI: 10.1016/s0895-7061(00)01279-6. View

Scheerer M, Rist R, Proske O, Meng A, Kostev K . Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metab Syndr Obes. 2016; 9:337-345. PMC: 5096728. DOI: 10.2147/DMSO.S116243. View

Kim M, Ko S, Kim B, Kang E, Noh J, Kyung Kim S . 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea. Diabetes Metab J. 2019; 43(4):398-406. PMC: 6712226. DOI: 10.4093/dmj.2019.0137. View

Shulman G . Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014; 371(12):1131-41. DOI: 10.1056/NEJMra1011035. View

Traina S, Slee A, Woo S, Canovatchel W . The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes. Diabetes Ther. 2015; 6(4):611-625. PMC: 4674477. DOI: 10.1007/s13300-015-0145-8. View

10.

Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino T, Tripathy D . Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124(2):509-14. PMC: 3904617. DOI: 10.1172/JCI70704. View

11.

Kohan D, Fioretto P, Tang W, List J . Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2013; 85(4):962-71. PMC: 3973038. DOI: 10.1038/ki.2013.356. View

12.

Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle H, Broedl U . Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2013; 16(3):215-22. DOI: 10.1111/dom.12182. View

13.

Feldstein A, Nichols G, Smith D, Stevens V, Bachman K, Rosales A . Weight change in diabetes and glycemic and blood pressure control. Diabetes Care. 2008; 31(10):1960-5. PMC: 2551635. DOI: 10.2337/dc08-0426. View

14.

Foster G, Borradaile K, Sanders M, Millman R, Zammit G, Newman A . A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009; 169(17):1619-26. PMC: 2879275. DOI: 10.1001/archinternmed.2009.266. View

15.

Scheen A, Van Gaal L . Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014; 2(11):911-22. DOI: 10.1016/S2213-8587(14)70004-X. View

16.

Igarashi T, Kawato H, KAMOSHITA S, Nosaka K, Seiya K, Hayakawa H . Acute tubulointerstitial nephritis with uveitis syndrome presenting as multiple tubular dysfunction including Fanconi's syndrome. Pediatr Nephrol. 1992; 6(6):547-9. DOI: 10.1007/BF00866499. View

17.

Smith A, Singleton J . Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complications. 2013; 27(5):436-42. PMC: 3766404. DOI: 10.1016/j.jdiacomp.2013.04.003. View

18.

Jones D, Miller M, Wofford M, Anderson Jr D, Cameron M, Willoughby D . The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. Am J Hypertens. 2000; 12(12 Pt 1-2):1175-80. DOI: 10.1016/s0895-7061(99)00123-5. View

19.

Chen L, Pei J, Kuang J, Chen H, Chen Z, Li Z . Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism. 2014; 64(2):338-47. DOI: 10.1016/j.metabol.2014.10.018. View

20.

Vivian E . Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm. 2015; 72(5):361-72. DOI: 10.2146/ajhp140168. View